Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2001

View Archived Issues

Celltech highlights 2000 developments; completes integration of merged businesses

Semaxanib (SU-5416) combination therapy enters phase III for advanced colorectal cancer

Pharmacoeconomic evaluation of Natrecor for treatment of acute heart failure

New technique for creating altered tumor antigens for cancer vaccines

Choice of oral antidiabetic predicts mortality in CAD patients

Schering AG spin-off to focus on cancer therapeutics

Several new human calcium channel transport proteins identified by HGS

P&G and Gene Logic identify new gene targets with potential to promote bone formation

Final results from phase II SomatoKine trial in type 2 diabetes

Metabasis and Sankyo extend collaboration for development of gluconeogenesis inhibitors

Clinical evaluation of NeoPharm's LE-AON commences

Adolor's opioid gastrointestinal drug enters late-stage clinical development

Lion Bioscience completes acquisition of Trega Biosciences

Pfizer's atorvastatin is focus of several studies at ACC sessions

Erythroid lineage discovered to be involved in etiology of transmissible spongiform encephalopathies

Syk antisense oligodeoxynucleotides as a therapeutic option for asthma

Cerivastatin improves LV remodeling in rats after MI

Mucociliary clearance enhanced by the P2Y2 agonist INS-365 in smokers

Long-term protection against allergic inflammation provided by SRL-172 in mice

ETA receptor blockade effective in rat model of pulmonary hypertension

MRS-1754 inhibits human mast cell degranulation via adenosine A2B receptor antagonism

Thyroid hormone analogue shows good tolerance and beneficial effects in heart failure

Urea and thiourea derivatives as CCR3 receptor antagonists

New selective 5-HT2C agonists from Lilly useful for obesity and depression

Fungally produced HIV integrase inhibitors identified at Merck & Co.

Berlex presents novel anticoagulants

Uroselective alpha1-adrenoceptor antagonists under study at Recordati

Yuhan researchers discover new series of protein farnesyltransferase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...